title: Predicting risk of bladder cancer using clinical and demographic information from prostate, lung, colorectal, and ovarian cancer screening trial participants.
abstract: BACKGROUND
  Effective screening and prevention strategies for bladder cancer require accurate risk stratification models. We developed models to predict the risk of bladder cancer based on clinical and sociodemographic data on participants in the Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) screening trial.
  
  
  METHODS
  Baseline clinical and sociodemographic data were obtained from 149,542 PLCO participants, ages 55 to 74 years, without a prior history of bladder cancer. Cox proportional hazards models were used to predict the risk of all bladder cancers (ABC) and of high-grade bladder cancers (HGBC) from baseline information. We used the HGBC risk model to design a hypothetical bladder cancer mortality prevention trial.
  
  
  RESULTS
  Over a median follow-up of 12 years, 1,124 men and 259 women developed bladder cancer (including 392 and 72 with HGBC, respectively). The incidence in men and in women was 133.6 and 29.6 cases per 100,000 person-years, respectively. Nomograms constructed for predicting the risk of ABC and HGBC had c-indices of 0.746 and 0.759, respectively. Age, race, education, smoking (intensity and duration), comorbidity, prostatitis, syphilis, and hormone replacement therapy use were statistically significant predictors in the models. We show that our risk model can be used to design a bladder cancer mortality prevention trial half the size of a trial designed without risk stratification.
  
  
  CONCLUSIONS
  Models to predict the risk of ABC and HGBC have been developed and validated.
  
  
  CONCLUSIONS
  Using the upper 40th percentile from the HGBC model, a suitable cohort for a screening or chemoprevention trial could be identified, although the size and follow-up of such a trial would be costly.
authors.affiliation: Authors' Affiliations: Center for Urologic Oncology, Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland, Ohio; Division of Urologic Surgery, Washington University School of Medicine, St. Louis, Missouri; Divisions of Cancer Epidemiology and Genetics and Cancer Prevention, National Cancer Institute, Bethesda, Maryland; and Division of Urology, Brigham and Women's Hospital, Harvard University Medical School, Boston, Massachusetts.
authors.forename: Maria C
authors.initials: MC
authors.lastname: Mir
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Stephenson
authors.forename: Robert L
authors.initials: RL
authors.lastname: Grubb
authors.forename: Amanda
authors.initials: A
authors.lastname: Black
authors.forename: Adam S
authors.initials: AS
authors.lastname: Kibel
authors.forename: Grant
authors.initials: G
authors.lastname: Izmirlian
mesh_terms: D000368:Aged; D015331:Cohort Studies; D015179:Colorectal Neoplasms / Q000453:epidemiology; D055088:Early Detection of Cancer; D005260:Female; D006801:Humans; D015994:Incidence; D008175:Lung Neoplasms / Q000453:epidemiology; D008297:Male; D008403:Mass Screening / Q000379:methods / Q000706:statistics & numerical data; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000453:epidemiology; D011471:Prostatic Neoplasms / Q000453:epidemiology; D014481:United States / Q000453:epidemiology; D001749:Urinary Bladder Neoplasms / Q000453:epidemiology* / Q000401:mortality / Q000473:pathology